Literature DB >> 15367651

T-cell responses to the M3 immune evasion protein of murid gammaherpesvirus 68 are partially protective and induced with lytic antigen kinetics.

Joshua J Obar1, Douglas C Donovan, Sarah G Crist, Ondine Silvia, James P Stewart, Edward J Usherwood.   

Abstract

DNA vaccination with the M3 gene, encoding an immune evasion molecule expressed during both the acute lytic and persistent phases of murid gammaherpesvirus 68 infection, yielded a significantly lower titer of virus in the lung than controls. The protection seen was dependent on T cells, and we mapped an epitope recognized by CD8 T cells. The immune response to this epitope follows the same kinetics as lytic cycle antigens, despite the fact that this gene is expressed in both lytic and persistent stages of infection. This has important implications for our understanding of T-cell responses to putative latency-associated gammaherpesvirus proteins and how vaccination may improve control of these viruses.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15367651      PMCID: PMC516430          DOI: 10.1128/JVI.78.19.10829-10832.2004

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  29 in total

1.  Critical role for a high-affinity chemokine-binding protein in gamma-herpesvirus-induced lethal meningitis.

Authors:  Victor van Berkel; Beth Levine; Sharookh B Kapadia; James E Goldman; Samuel H Speck; Herbert W Virgin
Journal:  J Clin Invest       Date:  2002-04       Impact factor: 14.808

2.  Latent antigen vaccination in a model gammaherpesvirus infection.

Authors:  E J Usherwood; K A Ward; M A Blackman; J P Stewart; D L Woodland
Journal:  J Virol       Date:  2001-09       Impact factor: 5.103

Review 3.  Murine gammaherpesvirus 68: a model for the study of gammaherpesvirus pathogenesis.

Authors:  J P Simas; S Efstathiou
Journal:  Trends Microbiol       Date:  1998-07       Impact factor: 17.079

Review 4.  Natural history of murine gamma-herpesvirus infection.

Authors:  A A Nash; B M Dutia; J P Stewart; A J Davison
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2001-04-29       Impact factor: 6.237

5.  T-cell vaccination alters the course of murine herpesvirus 68 infection and the establishment of viral latency in mice.

Authors:  L Liu; E J Usherwood; M A Blackman; D L Woodland
Journal:  J Virol       Date:  1999-12       Impact factor: 5.103

6.  Identification of a gammaherpesvirus selective chemokine binding protein that inhibits chemokine action.

Authors:  V van Berkel; J Barrett; H L Tiffany; D H Fremont; P M Murphy; G McFadden; S H Speck; I V Virgin HW
Journal:  J Virol       Date:  2000-08       Impact factor: 5.103

7.  Analysis of a novel strain of murine gammaherpesvirus reveals a genomic locus important for acute pathogenesis.

Authors:  A I Macrae; B M Dutia; S Milligan; D G Brownstein; D J Allen; J Mistrikova; A J Davison; A A Nash; J P Stewart
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

Review 8.  A mouse model for infectious mononucleosis.

Authors:  Emilio Flaño; David L Woodland; Marcia A Blackman
Journal:  Immunol Res       Date:  2002       Impact factor: 4.505

9.  A secreted chemokine binding protein encoded by murine gammaherpesvirus-68 is necessary for the establishment of a normal latent load.

Authors:  A Bridgeman; P G Stevenson; J P Simas; S Efstathiou
Journal:  J Exp Med       Date:  2001-08-06       Impact factor: 14.307

10.  Control of gammaherpesvirus latency by latent antigen-specific CD8(+) T cells.

Authors:  E J Usherwood; D J Roy; K Ward; S L Surman; B M Dutia; M A Blackman; J P Stewart; D L Woodland
Journal:  J Exp Med       Date:  2000-10-02       Impact factor: 14.307

View more
  7 in total

1.  CTCF and Sp1 interact with the Murine gammaherpesvirus 68 internal repeat elements.

Authors:  Hannah C Stevens; Kevin S-W Cham; David J Hughes; Ren Sun; Jeffery T Sample; Vivien J Bubb; James P Stewart; John P Quinn
Journal:  Virus Genes       Date:  2012-06-16       Impact factor: 2.332

Review 2.  Prospects of a novel vaccination strategy for human gamma-herpesviruses.

Authors:  Ting-Ting Wu; Marcia A Blackman; Ren Sun
Journal:  Immunol Res       Date:  2010-12       Impact factor: 2.829

3.  Induction of protective immunity against murine gammaherpesvirus 68 infection in the absence of viral latency.

Authors:  Qingmei Jia; Michael L Freeman; Eric J Yager; Ian McHardy; Leming Tong; DeeAnn Martinez-Guzman; Tammy Rickabaugh; Seungmin Hwang; Marcia A Blackman; Ren Sun; Ting-Ting Wu
Journal:  J Virol       Date:  2009-12-16       Impact factor: 5.103

4.  Cell-mediated immunity to Toxoplasma gondii develops primarily by local Th1 host immune responses in the absence of parasite replication.

Authors:  Jason P Gigley; Barbara A Fox; David J Bzik
Journal:  J Immunol       Date:  2009-01-15       Impact factor: 5.422

Review 5.  KSHV targeted therapy: an update on inhibitors of viral lytic replication.

Authors:  Natacha Coen; Sophie Duraffour; Robert Snoeck; Graciela Andrei
Journal:  Viruses       Date:  2014-11-24       Impact factor: 5.048

6.  ORF6 and ORF61 Expressing MVA Vaccines Impair Early but Not Late Latency in Murine Gammaherpesvirus MHV-68 Infection.

Authors:  Baila Samreen; Sha Tao; Karsten Tischer; Heiko Adler; Ingo Drexler
Journal:  Front Immunol       Date:  2019-12-18       Impact factor: 7.561

7.  Deletion of immune evasion genes provides an effective vaccine design for tumor-associated herpesviruses.

Authors:  Gurpreet Brar; Nisar A Farhat; Alisa Sukhina; Alex K Lam; Yong Hoon Kim; Tiffany Hsu; Leming Tong; Wai Wai Lin; Carl F Ware; Marcia A Blackman; Ren Sun; Ting-Ting Wu
Journal:  NPJ Vaccines       Date:  2020-11-05       Impact factor: 7.344

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.